Abstract
This report describes a new animal model for active, specific, systemic immunotherapy of leukemia. Mice were challenged (day 0) with 10(3) viable LSTRA cells and treated later with a vaccine containing 10(7) irradiated LSTRA cells. Four intraperitoneal or intravenous vaccine injections, on days 2, 9, 16 and 23, caused significant prolongation of survival; single injections by the same routes had inconsistent effects. Vaccine was not effective against a higher initial challenge dose, when given later in the course of tumor growth, when given intradermally or when used in weanling mice. The therapeutic effect was specific since a vaccine composed of an antigenically unrelated leukemia was ineffective. These results suggest that LSTRA is suitable for studying active, systemic, specific immunotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
